The pharmacokinetics of fondaparinux sodium in healthy volunteers

Clinical Pharmacokinetics

Volumn 41, Issue SUPPL. 2, 2002, Pages 1-9

  Donat, F ^a   Duret, J P ^a   Santoni, A ^a   Cariou, R ^a   Necciari, J ^a   Magnani, H ^b   De Greef, R ^b  

^a SANOFI   (France)

^b NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; FONDAPARINUX;

ADULT; AGED; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ARTICLE; BLOOD VOLUME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; STEADY STATE; URINE; VEIN THROMBOSIS;

EID: 0036395978     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241002-00001     Document Type: Article

References (20)

1. Hirsh J, Weitz JI. New antithrombotic agents. Lancet 1999; 353: 1431-6
2. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-9
3. Shetty HG, Woods F, Routledge PA. The pharmacology of oral anticoagulants: implications for therapy. J Heart Valve Dis 1993; 2: 53-62
4. Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 676-83
5. Schenk JF, Glusa E, Radziwon P, et al. A recombinant hirudin (IK-HIR01) in healthy volunteers. II. Effects on platelet adhesion and platelet-induced thrombin generation time. Haemostasis 1996; 26: 187-94
6. Linder R, Blomback M, Egberg N, et al. Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C. Thromb Res 1999; 95: 117-25
7. Herbert JM, Petitou M, Lormeau JC, et al. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997; 15: 1-26
8. Choay J, Petitou M, Lormeau JC, et al. Structure-activity relationship in heparin: a synthetic fondaparinux sodium with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116:492-9
9. Olson ST, Björk I, Sheffer R, et al. Role of the antithrombin-binding fondaparinux sodium in heparin acceleration of antithrombin-proteinase reactions: resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267: 12528-38
10. Paolucci F, Clavies MC, Donat FA, et al. Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet 2002; 41 Suppl. 2: 11-18
11. Lieu C, Shi J, Donat FA, et al. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs. Clin Pharmacokinet 2002; 41 Suppl. 2: 19-26
12. Lassen MR. Efficacy of the first synthetic factor Xa inhibitor, pentasaccharide Org31540/SR90107A, versus low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) following elective hip replacement surgery: The Ephesus study [abstract]. Thromb Haemost 2001; 86 Suppl.: OC45
13. Ollier C, Santoni A, Faaij RA, et al. Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers. Clin Pharmacokinet 2002; 41 Suppl. 2: 31-37
14. Mant T, Fournié P, Ollier C, et al. Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers. Clin Pharmacokinet 2002; 41 Suppl. 2: 39-45
15. Faaij RA, Burggraaf J, Schoemaker RC, et al. The synthetic pentasaccharide fondaparinux sodium does not interact with oral warfarin (Short Communication). Clin Pharmacokinet 2002; 41 Suppl. 2: 27-9
16. Paolucci F, Clavies MC, Donat FA, et al. The mechanism of action of pentasaccharide (Arixtra®, fondaparinux sodium): identification of specific binding to purified and human plasma-derived proteins [abstract]. The International Society on Thrombosis and Haemostasis XVIII Congress; 2001 Jul 6-12; Thromb Haemost 2001, 86 Suppl.
17. Turpie AG, Gallus AS, Hoek JA and the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619-25
18. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-10
19. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-20
20. Turpie AGG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359; 1721-6